| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
45,333 | 40,755 | 31,824 | 26,521 | 18,550 |
| Cost of Revenue
|
-19,080 | -16,916 | -7,915 | -7,711 | -8,402 |
|
Gross Profit
|
26,253 | 23,839 | 23,909 | 18,810 | 10,148 |
| Selling, General and Administrative Expenses
|
-16,664 | -15,657 | -12,152 | -11,658 | -17,414 |
|
Research and Development Expenses
|
-8,457 | -7,526 | -4,495 | -3,557 | -3,824 |
| Depreciation, Amortization and Depletion
|
-187 | -187 | -155 | -2,765 | -992 |
|
Operating Income/Expenses
|
-25,308 | -23,370 | -16,802 | -17,980 | -22,230 |
|
Total Operating Profit/Loss
|
945 | 469 | 7,107 | 830 | -12,082 |
| Total Net Finance Income/Expense
|
487 | 731 | 380 | -561 | -314 |
| Net Investment Income
|
535 | 535 | -60 | 54 | 260 |
| Irregular Income/Expenses
|
-262 | -262 | -387 | -6,329 | -647 |
|
Other Income/Expense, Non-Operating
|
0 | 0 | -39 | -83 | 0 |
|
Non-Operating Income/Expenses, Total
|
760 | 1,004 | -106 | -6,919 | -701 |
|
Pretax Income
|
1,705 | 1,473 | 7,001 | -6,089 | -12,783 |
|
Provision for Income Tax
|
-557 | -510 | -1,221 | 482 | 327 |
|
Net Income from Continuing Operations
|
1,148 | 963 | 5,780 | -5,607 | -12,456 |
|
Discontinued Operations
|
0 | 0 | 0 | 82 | -695 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
1,148 | 963 | 5,780 | -5,525 | -13,151 |
|
Net Income after Non-Controlling/Minority Interests
|
1,148 | 963 | 5,780 | -5,525 | -13,151 |
|
Net Income Available to Common Stockholders
|
1,148 | 963 | 5,780 | -5,525 | -13,151 |
|
Dilution to Earnings
|
-- | -- | -- | -- | 0 |
|
Diluted Net Income Available to Common Stockholders
|
1,148 | 963 | 5,780 | -5,525 | -13,151 |
| Basic EPS
|
0.01 | 0.01 | 0.09 | -0.14 | -0.42 |
| Diluted EPS
|
0.01 | 0.01 | 0.08 | -0.14 | -0.42 |
|
Basic Weighted Average Shares Outstanding
|
68,316.75 | 70,827 | 66,438 | 41,435 | 31,594 |
|
Diluted Weighted Average Shares Outstanding
|
71,928.75 | 74,439 | 71,876 | 41,435 | 31,594 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
1,160 | 684 | 6,599 | -5,775 | -12,586 |
|
EBITDA
|
1,822 | 1,822 | 7,511 | -4,623 | -10,543 |
|
Normalized EBITDA
|
4,400 | 4,400 | 9,400 | 5,200 | -8,500 |
12/31/2022 - 2/1/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade